Tokyo Tape
Sign in
← H.U. Group Holdings

Quarterly report · Q1

4544.TEDINET S100OZDP
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥65.3bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥272.9bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥63.5bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥8.6bn2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥12.2bn2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥8.5bn2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥47.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.9bn2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥8.1bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥11.4bn2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥5.6bn2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥8.3bn2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥278.3bnat 2022-06-30Cons.Assets
Total assets¥286.6bnat 2022-03-31Cons.Assets
Total assets¥250.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥132.3bnat 2022-06-30Cons.Liabilities
Total liabilities¥146.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥146.0bnat 2022-06-30Cons.Net assets
Net assets / equity¥140.2bnat 2022-03-31Cons.Net assets
Net assets / equity¥118.5bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥39.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥46.5bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥39.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥46.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.3bnat 2021-06-30Cons.Cash and cash equivalents
Cash & equivalents¥43.0bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.6bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7.3bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥8.0bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥98.252022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.32021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥98.242022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232021-04-01 → 2021-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio52.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio47.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥607m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥43.4bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥27m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥15.0bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2022-04-01 → 2022-06-30¥440m
—segment totalrevenue2022-04-01 → 2022-06-30¥68.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥65.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.5bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.2bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥502m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥41.7bn
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥14m
jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥6.7bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥16.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥14.4bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.4bn
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5m
jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2021-04-01 → 2021-06-30¥821m
—segment totalrevenue2021-04-01 → 2021-06-30¥65.4bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥63.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥2.0bn
—segment totalsegment profit2021-04-01 → 2021-06-30¥12.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 460
ItemContextValueUnit
LiabilitiesPrior1YearInstant146408000000JPY
LiabilitiesCurrentQuarterInstant132272000000JPY
Capital stockPrior1YearInstant9231000000JPY
Capital stockCurrentQuarterInstant9233000000JPY
Capital surplusPrior1YearInstant24953000000JPY
Capital surplusCurrentQuarterInstant24955000000JPY
Retained earningsPrior1YearInstant103957000000JPY
Retained earningsCurrentQuarterInstant105942000000JPY
Treasury stockPrior1YearInstant-2081000000JPY
Treasury stockCurrentQuarterInstant-2082000000JPY
Shareholders equityPrior1YearInstant136060000000JPY
Shareholders equityCurrentQuarterInstant138049000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1620000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant1326000000JPY
Foreign currency translation adjustmentPrior1YearInstant3997000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant8072000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-1573000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1521000000JPY
Valuation and translation adjustmentsPrior1YearInstant4045000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant7878000000JPY
Subscription rights to sharesPrior1YearInstant72000000JPY
Subscription rights to sharesCurrentQuarterInstant75000000JPY
Net assetsPrior1YearInstant140178000000JPY
Net assetsCurrentQuarterInstant146002000000JPY
Liabilities and net assetsPrior1YearInstant286587000000JPY
Liabilities and net assetsCurrentQuarterInstant278275000000JPY
Net salesPrior1YTDDuration63492000000JPY
Net salesCurrentYTDDuration65331000000JPY
Cost of salesPrior1YTDDuration38136000000JPY
Cost of salesCurrentYTDDuration40435000000JPY
Gross profitPrior1YTDDuration25356000000JPY
Gross profitCurrentYTDDuration24896000000JPY
Selling general and administrative expensesPrior1YTDDuration13129000000JPY
Selling general and administrative expensesCurrentYTDDuration16315000000JPY
Operating incomePrior1YTDDuration12227000000JPY
Operating incomeCurrentYTDDuration8580000000JPY
Interest income noiPrior1YTDDuration9000000JPY
Interest income noiCurrentYTDDuration24000000JPY
Dividends income noiPrior1YTDDuration20000000JPY
Dividends income noiCurrentYTDDuration27000000JPY
Foreign exchange gains noiPrior1YTDDuration－JPY
Foreign exchange gains noiCurrentYTDDuration598000000JPY
Other noiPrior1YTDDuration592000000JPY
Other noiCurrentYTDDuration158000000JPY
Non operating incomePrior1YTDDuration622000000JPY
Non operating incomeCurrentYTDDuration809000000JPY
Interest expenses noePrior1YTDDuration97000000JPY
Interest expenses noeCurrentYTDDuration95000000JPY
Equity in losses of affiliates noePrior1YTDDuration703000000JPY
Equity in losses of affiliates noeCurrentYTDDuration768000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass